BeiGene-283: Phase I data

Data from 29 evaluable patients with BRAF, K-Ras (KRAS) or neuroblastoma Ras viral (v-Ras) oncogene (NRAS) mutation-positive solid tumors in an open-label, dose-escalation, Australian and New Zealan...